Multitarget Stool DNA Predicts Colorectal Neoplasia
By LabMedica International staff writers Posted on 25 Mar 2020 |
Image: Multitarget Stool DNA Screening has a high positive predictive value for colorectal neoplasia regardless of exposure to previous colonoscopy (Photo courtesy of Madeline Morr).
Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Screening is effective for preventing and decreasing deaths from colorectal cancer.
Screening, by one of a number of methods, is recommended starting from the age of 50 to 75. Multitarget stool DNA (MT-sDNA) testing has grown as a noninvasive screening modality for colorectal cancer (CRC), but real-world clinical data are limited in the post-FDA approval setting. The effect of previous colonoscopy on MT-sDNA performance is not known.
A large team of Medical Specialists at the Mayo Clinic (Rochester, MN, USA) evaluated findings of colorectal neoplasia (CRN) at diagnostic colonoscopy in patients with positive MT-sDNA testing, stratified by patient exposure to previous colonoscopy. They identified consecutive patients completing MT-sDNA testing over a 39-month period and reviewed the records of those with positive tests for neoplastic findings at diagnostic colonoscopy. MT-sDNA test positivity rate, adherence to diagnostic colonoscopy, and the positive predictive value (PPV) of MT-sDNA for any CRN and neoplastic subtypes were calculated. The team noted that MT-sDNA testing amplifies methylated BMP3 and NDRG4, mutant KRAS and beta-actin and measures hemoglobin through immunochemical testing.
The team reported that of 16,469 completed tests, 2,326 patients received positive results (14.1%), and after excluding those with increased risk for CRC, 1,558 of the 1,801 remaining patients (87%) underwent diagnostic colonoscopy. Of these patients, 918 had undergone previous colonoscopy (59%). The investigators determined that any colorectal neoplasia was found in 1,046 of patients who underwent diagnostic colonoscopy (positive predictive value = 67%). Although more neoplastic lesions were found in patients without previous colonoscopy (73%), rates were still high among those who had (63%).
The authors concluded that MT-sDNA has a high PPV for any CRN regardless of exposure to previous colonoscopy. Right-sided CRN was found at colonoscopy in most patients with positive MT-sDNA testing, representing a potential advantage over other currently available screening modalities for CRC. The study was published ahead of print on February 17, 2020 in The American Journal of Gastroenterology.
Related Links:
Mayo Clinic
Screening, by one of a number of methods, is recommended starting from the age of 50 to 75. Multitarget stool DNA (MT-sDNA) testing has grown as a noninvasive screening modality for colorectal cancer (CRC), but real-world clinical data are limited in the post-FDA approval setting. The effect of previous colonoscopy on MT-sDNA performance is not known.
A large team of Medical Specialists at the Mayo Clinic (Rochester, MN, USA) evaluated findings of colorectal neoplasia (CRN) at diagnostic colonoscopy in patients with positive MT-sDNA testing, stratified by patient exposure to previous colonoscopy. They identified consecutive patients completing MT-sDNA testing over a 39-month period and reviewed the records of those with positive tests for neoplastic findings at diagnostic colonoscopy. MT-sDNA test positivity rate, adherence to diagnostic colonoscopy, and the positive predictive value (PPV) of MT-sDNA for any CRN and neoplastic subtypes were calculated. The team noted that MT-sDNA testing amplifies methylated BMP3 and NDRG4, mutant KRAS and beta-actin and measures hemoglobin through immunochemical testing.
The team reported that of 16,469 completed tests, 2,326 patients received positive results (14.1%), and after excluding those with increased risk for CRC, 1,558 of the 1,801 remaining patients (87%) underwent diagnostic colonoscopy. Of these patients, 918 had undergone previous colonoscopy (59%). The investigators determined that any colorectal neoplasia was found in 1,046 of patients who underwent diagnostic colonoscopy (positive predictive value = 67%). Although more neoplastic lesions were found in patients without previous colonoscopy (73%), rates were still high among those who had (63%).
The authors concluded that MT-sDNA has a high PPV for any CRN regardless of exposure to previous colonoscopy. Right-sided CRN was found at colonoscopy in most patients with positive MT-sDNA testing, representing a potential advantage over other currently available screening modalities for CRC. The study was published ahead of print on February 17, 2020 in The American Journal of Gastroenterology.
Related Links:
Mayo Clinic
Latest Molecular Diagnostics News
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access